Ipca Labs, Medicines for Malaria Venture ink pact for antimalarial co-formulation Atoguanil

"Today, the manufacturing cost of atovaquone is believed to pose a barrier to the widespread use of atovaquone-proguanil based products in malaria-endemic countries," Ipca Labs said.

New Delhi: Drug firm Ipca Laboratories on Friday said it has entered into an agreement with Medicines for Malaria Venture to jointly develop a novel antimalarial co-formulation named 'Atoguanil'. Atoguanil contains the active pharmaceutical ingredients atovaquone and proguanil, Ipca Laboratories said in a BSE filing.

"Today, the manufacturing cost of atovaquone is believed to pose a barrier to widespread use of atovaquone-proguanil based products in malaria-endemic countries," it added.

Read Also: Ipca Labs Gujarat facility red-flagged by USFDA for non-compliance with CGMP

Atoguanil has the potential to provide a lower cost alternative, making such products more accessible to people living in malaria-endemic countries for prophylaxis, Ipca Laboratories said.

Read Also: Ipca Labs gets 3 USFDA observations for Silvassa unit